Aiforia has developed multiple AI models that are CE-marked under IVDD for breast cancer (ER, PR, Ki-67 scoring), prostate cancer (Gleason grading), and lung cancer (PD-L1 scoring) [66]. This evidence concerns the gene CD274 and breast carcinoma.